Search
引用資料與參考文獻 (1)
Invitrogen™
LentiArray™ CRISPR Positive Control Lentivirus, human HPRT
Optimizing delivery conditions is a critical step in any experiment utilizing the CRISPR/Cas9 system. The Invitrogen™ LentiArray™ CRISPR Positive Control深入閱讀
Have Questions?
變更視圖
| 產品號碼 | Quantity |
|---|---|
| A32056 | 100 μL |
| A32829 | 1 mL |
產品號碼 A32056
價格 (TWD)
14,910.00
線上優惠
Ends: 31-Dec-2025
21,300.00您節省 6,390.00 (30%)
Each
Quantity:
100 μL
價格 (TWD)
14,910.00
線上優惠
Ends: 31-Dec-2025
21,300.00您節省 6,390.00 (30%)
Each
Optimizing delivery conditions is a critical step in any experiment utilizing the CRISPR/Cas9 system. The Invitrogen™ LentiArray™ CRISPR Positive Control Lentivirus gRNA against HPRT is a highly efficient gRNA validated in multiple human cell lines that has achieved editing efficiencies of greater than 80%. It can be used to rapidly determine ideal delivery conditions in order to achieve maximum editing efficiency in your cell model of choice.
For Research Use Only. Not for use in diagnostic procedures.
規格
Control TypePositive Control
Delivery TypeLentiviral
For Use With (Application)CRISPR gene knockout
Product LineLentiArray
Product TypeCRISPR Positive Control Lentivirus
Quantity100 μL
Shipping ConditionDry Ice
PromoterU6
SpeciesHuman
Transfection TechniqueLentiviral transduction
Unit SizeEach
內容物與存放
1 x 100 μL. Store (at -68°C to -85°C.)
引用資料與參考文獻 (1)
引用資料與參考文獻
Abstract
A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain.
Journal:Pediatr Blood Cancer
PubMed ID:28398638
Malignant rhabdoid tumors (MRTs) are deadly embryonal tumors of the infancy. With poor survival and modest response to available therapies, more effective and less toxic treatments are needed. We hypothesized that a systematic screening of the kinome will reveal kinases that drive rhabdoid tumors and can be targeted by specific